Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$274.76 +3.3%	$296.08	$253.30 ▼ $346.85	$147.74B	0.51	2.77 million shs	4.21 million shs
BIIB Biogen	$124.40 +5.3%	$128.33	$110.04 ▼ $238.00	$18.23B	0.12	1.37 million shs	2.55 million shs
GILD Gilead Sciences	$103.82 +7.1%	$107.23	$62.07 ▼ $119.96	$129.27B	0.26	7.62 million shs	12.93 million shs
SGEN Seagen	$228.74	$228.74	$123.77 ▼ $228.96	$42.93B	0.32	1.48 million shs	86 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	0.00%	-5.46%	-7.04%	-9.81%	-14.28%
BIIB Biogen	0.00%	-4.31%	+2.63%	-17.08%	-46.64%
GILD Gilead Sciences	0.00%	-6.58%	-6.53%	+1.45%	+46.85%
SGEN Seagen	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.6479 of 5 stars	3.2	2.0	4.2	3.9	3.5	2.5	0.6
BIIB Biogen	4.8531 of 5 stars	4.2	3.0	0.0	3.7	3.9	2.5	1.9
GILD Gilead Sciences	4.9173 of 5 stars	2.4	5.0	4.2	4.1	4.0	2.5	1.9
SGEN Seagen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.39	Hold	$310.23	12.91% Upside
BIIB Biogen	2.38	Hold	$191.30	53.78% Upside
GILD Gilead Sciences	2.78	Moderate Buy	$110.55	6.48% Upside
SGEN Seagen	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GILD, SGEN, BIIB, and AMGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	AMGN Amgen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$235.00 ➝ $280.00
5/7/2025	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$207.00 ➝ $169.00
5/5/2025	BIIB Biogen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$185.00 ➝ $175.00
5/2/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$319.00 ➝ $315.00
5/2/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
5/2/2025	BIIB Biogen	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$205.00
5/2/2025	AMGN Amgen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$324.00 ➝ $320.00
5/2/2025	BIIB Biogen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$217.00 ➝ $205.00
5/2/2025	BIIB Biogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$265.00 ➝ $220.00
5/2/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$241.00 ➝ $187.00

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$34.13B	4.33	$27.53 per share	9.98	$10.93 per share	25.14
BIIB Biogen	$9.82B	1.86	$20.43 per share	6.09	$114.71 per share	1.08
GILD Gilead Sciences	$28.74B	4.50	$8.20 per share	12.66	$15.44 per share	6.72
SGEN Seagen	$2.30B	18.66	N/A	N/A	$15.10 per share	15.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	36.39	12.85	2.63	12.24%	176.32%	11.71%	N/A
BIIB Biogen	$1.63B	$10.13	11.12	7.53	1.51	16.87%	14.98%	8.76%	N/A
GILD Gilead Sciences	$480M	$4.75	280.59	12.80	0.71	1.67%	31.63%	10.38%	N/A
SGEN Seagen	-$610.31M	-$4.01	N/A	N/A	N/A	-32.61%	-28.06%	-20.92%	N/A

Latest GILD, SGEN, BIIB, and AMGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.46%	+8.53%	86.86%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	3.04%	+2.74%	66.53%	10 Years
SGEN Seagen	N/A	N/A	N/A	N/A	N/A

Latest GILD, SGEN, BIIB, and AMGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/25/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025
3/4/2025	AMGN Amgen	quarterly	$2.38	3.05%	5/16/2025	5/16/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	9.62	1.26	0.95
BIIB Biogen	0.27	1.35	0.90
GILD Gilead Sciences	1.24	1.50	1.20
SGEN Seagen	N/A	2.67	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
GILD Gilead Sciences	83.67%
SGEN Seagen	84.26%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.76%
BIIB Biogen	0.16%
GILD Gilead Sciences	0.27%
SGEN Seagen	25.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	25,200	537.71 million	533.50 million	Optionable
BIIB Biogen	8,720	146.53 million	146.14 million	Optionable
GILD Gilead Sciences	17,000	1.25 billion	1.24 billion	Optionable
SGEN Seagen	3,256	187.70 million	139.08 million	Optionable

GILD, AMGN, BIIB, and SGEN Headlines

Recent News About These Companies

Trial win sets up new use for Astellas, Seagen's Padcev in bladder cancer

March 16, 2025 | pharmaphorum.com

Merck in "advanced talks" for $40bn Seagen bid; report

March 7, 2025 | pharmaphorum.com

Seagen posts breast cancer win ahead of Pfizer takeover

February 23, 2025 | pharmaphorum.com

Is Merck planning a $30bn-plus move for Seagen?

December 6, 2024 | pharmaphorum.com

Pfizer raises guidance as COVID franchise drives Q3 beat

October 30, 2024 | seekingalpha.com

Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed

October 30, 2024 | seekingalpha.com

Franklin Biotechnology Discovery C

October 5, 2024 | morningstar.com

Seagen wins Enhertu patent dispute with Daiichi Sankyo

July 20, 2024 | pharmaphorum.com

Pfizer: Turning The Corner (Rating Upgrade)

May 27, 2024 | seekingalpha.com

Two Brothers, a Big Biotech Bet and an $8 Billion Payout

April 13, 2024 | wsj.com

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

April 2, 2024 | pharmaphorum.com

Ron Baron Portfolio Magic: Building Your Financial Future

March 20, 2024 | msn.com

Bailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving markets

March 13, 2024 | msn.com

Pfizer shutting down Seagen's $350M construction project in Everett

March 1, 2024 | bizjournals.com

Neuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk Says

February 24, 2024 | finance.yahoo.com

MRNA Feb 2024 64.000 put

February 23, 2024 | finance.yahoo.com

MRNA Feb 2024 77.000 call

February 23, 2024 | finance.yahoo.com

Pfizer adds bull at Guggenheim on ex-COVID prospects

February 23, 2024 | msn.com

MRNA Feb 2024 67.000 put

February 22, 2024 | finance.yahoo.com

Pfizer touts cancer efforts in first Super Bowl commercial

February 12, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
By Chris Markoch | April 16, 2025
View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
2 Smart Investments to Follow Warren Buffett’s Lead
By Ryan Hasson | April 23, 2025
View 2 Smart Investments to Follow Warren Buffett’s Lead
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
By Jeffrey Neal Johnson | May 2, 2025
View 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

GILD, AMGN, BIIB, and SGEN Company Descriptions

Amgen NASDAQ:AMGN

$274.76 +8.90 (+3.35%)

Closing price 04:00 PM Eastern

Extended Trading

$274.82 +0.06 (+0.02%)

As of 08:00 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$124.40 +6.23 (+5.27%)

Closing price 04:00 PM Eastern

Extended Trading

$124.50 +0.10 (+0.08%)

As of 07:41 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences NASDAQ:GILD

$103.82 +6.91 (+7.13%)

Closing price 04:00 PM Eastern

Extended Trading

$103.51 -0.31 (-0.30%)

As of 07:58 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time